ISSN: 2165-7092
Pancreatic Disorders & Therapy
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business
 

Emerging Role of MicroRNA in Pancreatic Cancer

Jun Xia1, Fazlul H Sarkar2 and Zhiwei Wang1,3*
1Department of Biochemistry, Bengbu Medical College, Anhui, PR China
2Department of Pathology and Oncology, Karmanos Cancer Institute, Wayne State University, USA
3Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, USA
Corresponding Author : Zhiwei Wang
Department of Pathology, Beth Israel
Deaconess Medical Center
Harvard Medical School, Boston, USA
Tel: (617) 735-2474
Fax: (617) 735-2480
E-mail: zwang6@bidmc.harvard.edu
Received April 25, 2012; Accepted April 25, 2012; Published April 26, 2012
Citation: Xia J, Sarkar FH, Wang Z (2012) Emerging Role of Microrna in Pancreatic Cancer. Pancreat Disorders Ther 2:e114. doi:10.4172/2165-7092.1000e114
Copyright: © 2012 Xia J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Pancreatic Disorders & Therapy

Keywords
Pancreatic cancer; microRNA; Stem cell; Natural agents; Cancer therapy
Introduction
Pancreatic cancer (PC) is of the most highly aggressive malignant disease, and currently the fourth most frequent cause of cancer-related mortality in the United States [1]. It is expected that approximately 43,920 people are diagnosed with PC and about 37,390 will die of this disease in 2012 [1]. Despite recent therapeutic advancement, the median survival rate is less than 6 months, and 5-year survival rate is less than 5%. The high mortality and poor prognosis are due to extensive metastasis, lack of early symptoms, and lack of reliable early diagnostic markers [1]. Hence, it is important to understand the molecular mechanism(s) underlying this devastating disease in order to develop new therapeutic strategies for improving the therapeutic outcome of patients diagnosed with PC.
Emerging evidence suggests that microRNAs (miRNAs) play a pivotal role in the development and progression of PC [2]. It is well documented that miRNAs are a family of the 17-25-nucleotide-long non-coding RNAs that govern the expression of approximately 30% of the protein-coding genes in human genome [2]. The miRNAs repress translation or degrade the target mRNA through binding to the 3’UTR (3’ untranslated region) of target mRNA. It is worth mentioning that miRNAs could function as either oncogenes or tumor suppressor genes, suggesting that the expression of miRNAs could be dependent on tumor types [2]. Very interestingly, one individual miRNA could regulate more than hundred mRNA targets, whereas one gene could be controlled by several miRNAs [2].
There is a wealth of literature supporting that deregulation of miRNAs are involved in the development and progression of human malignancies including PC [2]. It has been reported that the expression profiles of miRNAs could provide clues to pancreatic tumorigenesis because miRNA expression profiles could differentiate among normal pancreas, chronic pancreatitis, and PC. For example, Roldo et al. [3] found that up-regulation of miR-103 and miR-107 as well as downregulation of miR-155 could be helpful to discriminate pancreatic tumors from the normal pancreas. We also found that miR-200 was down-regulated in the compound transgenic mice with activated K-ras and Ink4a/Arf deficiency that quickly develop pancreatic tumors [4]. Moreover, we identified up-regulation of miR-21, miR- 221, miR-27a, miR-27b and miR-155, and down-regulation of miR- 216a, miR-216b, miR-217 and miR-146a expression in tumors derived from this mouse model [5]. In addition, over-expression of miR-21 has been found to be associated with metastasis [3], and patients with increased miR-196a-2 have poor survival [6]. Consistent with these results, we also found that 37 miRNAs were decreased and 54 miRNAs were increased in the plasma of PC patients [7]. Specifically, miR-21 was up-regulated, whereas let-7 family and miR-146a were significantly down-regulated in the plasma of PC patients. More importantly, miR-21 expression was associated with worse survival, while let-7 expression was inversely correlated with survival [7]. These results suggest that unique miRNA signatures could be useful for the screening of high-risk patients and may serve as biological markers for disease status.
Multiple studies have demonstrated that miRNAs play pivotal roles in EMT (epithelial-to-mesenchymal transition) phenotype in PC. The EMT is a fundamental process whereby epithelial cells undergo conversion into mesenchymal cells. During EMT, cells lose epithelial characteristics with down-regulation of epithelial markers such as E-cadherin and γ-catenin, and gain the expression of mesenchymal markers including Vimentin, fibronectin, Twist, ZEB1, ZEB2, Slag, and Snail. Recently, it has been reported that miR-200 can directly target mesenchymal markers ZEB1 and ZEB2 in PC cell lines [8,9]. Consistent with this finding, we also found that miR-200 and let-7 family was down-regulated in gemcitabine resistant PC cells that have undergone EMT [10]. Very recently, one study showed that miR-126 play an essential role in the inhibition of invasive growth of PC cells through regulation of ADAM9 expression, leading to the induction of epithelial marker E-cadherin [11]. These published data suggest that miRNAs play critical roles in the acquisition of EMT.
Accumulating evidence suggests that miRNAs are involved in PC stem cells (CSCs). Pancreatic CSCs have been identified and isolated from human PC by flow cytometry using cell surface markers including CD44, CD24, ESA, CD133, and c-Met [12]. Recently, Ji et al. [13] identified that pancreatic CSCs have lower expression of miR- 34, indicating that miR-34 could be involved in pancreatic CSCs selfrenewal. Moreover, miR-34 was reported to govern pancreatic CSCs self-renewal through modulation of Notch and Bcl-2. Nalls et al. [14] reported that miR-34a is a critical regulator of pancreatic cancer progression through regulation of CSC characteristics. Moreover, differentially expressed miRNAs including miR-99a, miR-100 miR-125b, miR-192, and miR-429 have been reported in pancreatic CSCs [15]. Additionally, we demonstrated that miR-200b was downregulated in FoxM1 over-expressing or Notch-1 over-expressing PC cell lines, which have undergone EMT consistent with CSCs phenotype [16,17]. Taken together, miRNAs have been shown to play an important role in pancreatic CSCs self-renewal.
altered expression of specific miRNAs has been found to be involved in drug-resistant PC cells. Previous reports from our laboratory have shown that the expression of miR-200 family and let-7 family was significantly down-regulated in gemcitabine-resistant cells [10]. Moreover, we have demonstrated that re-expression of miR- 200 family resulted in increased cell sensitivity to gemcitabine [10]. In support of the role of miRNAs in drug resistance, Park et al. [18] found that anti-sense inhibition of miR-21 or miR-221 sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. In agreement with this concept, Giovannetti et al. [19] showed that over-expression of miR-21 significantly suppressed anti-tumor activity by gemcitabine, suggesting that targeting miR-21 could be beneficial for overcoming gemcitabine chemo-resistance. Taken together, these data suggest that the regulation of miRNA could make drug-resistant cells to become drug-sensitive, and such strategy could be helpful to overcome drug resistance in PC.
As deregulation of miRNAs such as miRNAs over-expression or down-regulation play critical roles in PC progression, targeting the mature miRNAs or their precursors by synthetic anti-sense olignucleotides or up-regulation of miRNAs ectopically could be a novel strategy for PC therapy. Indeed, one study revealed that transfection of the synthetic Gli-1-miRNA-3548 inhibited cell division and induced late apoptosis in PC cells [20]. Inhibition of miR-21 using anti-sense olignucleotides suppressed proliferation, and increased apoptosis in PC cell lines [18]. Similarly, over-expressions of miR-34 by using miR-34 mimics or infection with lentiviral miR-34 construct decreased cell clonogenicity and invasion as well as induced apoptosis [13]. Interestingly, several drugs have been reported to regulate the expression of miRNAs. For example, we found that metformin increased the expression of several miRNAs such as let-7a, let-7b, miR-26a, miR-101, miR-200b, and miR-200c [21].
Recently, accumulated evidence revealed that chemopreventive agents commonly known as natural compounds could target miRNAs to regulate the key cellular protein expression. Due to lack of toxicity, natural compounds have attracted more attention as chemopreventive agents to target miRNAs in recent years. We have shown that isoflavoned 3,3’-diindolylmethane (DIM) increased the expression of miR-200 family in PC cells [10]. More importantly, isoflavone or DIM treatment enhanced the sensitivity of gemcitabine-resistant cells to gemcitabine, which was in part mediated through up-regulation of miR-200 in PC cells [10]. Similarly, we demonstrated that curcumin increased PC cell sensitivity to gemcitabine through increased miR- 200 and decreased miR-21 [22]. Moreover, we found that CDF, a novel synthetic analog of curcumin, inhibited the sphere-forming ability of PC cells and suppressed tumor growth, which was associated with decreased miR-21 expression and increased miR-200 expression [22]. Furthermore, we demonstrated that CDF inhibited PC cell survival, migration, invasion and CSC function in part via up-regulation of multiple tumor suppressive miRNAs including let-7 family, miR- 26a, miR-101, miR-146a, and miR-200b [21]. Additionally, we found that genistein inhibited cell growth was partly mediated through upregulation of miR-200b in Notch-1 or FoxM1 over-expressing PC cells [16,17]. These results provide experimental evidence showing that natural compounds could function as miRNA regulators, suggesting that the regulation of miRNAs by nutraceuticals could be a novel strategy for achieving better treatment outcome of patients diagnosed with PC.
Collectively, these studies clearly suggest the important roles of miRNAs in cell growth, apoptosis, invasion, metastasis, EMT, stem cells self-renewal, and drug resistance. Therefore, identification of deregulated miRNAs in PC could be useful for tumor diagnosis, disease prognosis, and for assessing therapeutic outcome. Targeting miRNAs, specifically by natural compounds could open newer avenues for the prevention of tumor progression or treatment of PC. However, further in-depth investigation is required to fully understand how miRNAs are involved in the development and progression of PC, and finding which agents including natural compounds and how they could regulate the expression of distinct miRNAs. The answers will help us to design novel treatment strategies for the cure of PC patients.
References

Select your language of interest to view the total content in your interested language
 
Share This Article
   
 
   
 
Relevant Topics
Disc Acute Pancreatitis
Disc Acute Pancreatitis Symptoms
Disc Advanced Type 1 Diabetes Treatment
Disc Advanced Type 2 Diabetes Treatment
Disc Advances of Diabetes Cure
Disc Anal Cancer Diagnosis
Disc Biliary Dyskinesia
Disc Bladder Cancer Diagnosis
Disc Blood Cancer Diagnosis
Disc Brain Cancer Diagnosis
Disc Breast Cancer Diagnosis
Disc Cancer Diagnosis
Disc Cervical Cancer Diagnosis
Disc Childhood Diabetes
Disc Chronic Pancreatitis
Disc Colon Cancer Diagnosis
Disc Complications of Hyperglycemia
Disc Complications of Hypoglycemia
Disc Constipation
Disc Diabetes Cholestrol
Disc Diabetes Lipid Metabolism
Disc Diabetes Statistics
Disc Diabetes and Alcohol
Disc Diabetes and Weight Loss
Disc Diabetes for Dummies
Disc Digestive Enzymes
Disc Endoscopy
Disc Epigastric Pain
Disc Esophageal Cancer Diagnosis
Disc GIST Sarcoma
Disc Gall Bladder
Disc Gall Bladder Symptoms
Disc Gallbladder Disease
Disc Gallstone Pancreatitis
Disc Gastric Cancer
Disc Gastrointestinal Bleeding
Disc Gastrointestinal Hormones
Disc Gastrointestinal Infections
Disc Gastrointestinal Inflammation
Disc Gastrointestinal Pathology
Disc Gastrointestinal Pharmacology
Disc Gastrointestinal Radiology
Disc Gastrointestinal Surgery
Disc Gastrointestinal Tuberculosis
Disc Hereditary Pancreatitis
Disc Inflamed Pancreas
Disc Intestinal Blockage
Disc Kidney Cancer Diagnosis
Disc Latest Research on Diabetes
Disc Leukemia Diagnosis
Disc Liver Cancer Diagnosis
Disc Lung Cancer Diagnosis
Disc Lymphoma Diagnosis
Disc Mesothelioma Diagnosis
Disc Mouth Cancer Diagnosis
Disc Obesity and Diabetes
Disc Ovarian Cancer Diagnosis
Disc Pancreas
Disc Pancreas Anatomy
Disc Pancreas Pain
Disc Pancreatectomy
Disc Pancreatic Cancer Diagnosis
Disc Pancreatic Disorder
Disc Pancreatic Duct
Disc Pancreatic Enzyme Replacement Therapy
Disc Pancreatitis
Disc Pancreatitis Symptoms
Disc Pathophysiology of Diabetes
Disc Prostate Cancer Diagnosis
Disc Proton Therapy Pancreatic Cancer
Disc Rectal Cancer Diagnosis
Disc Reverse Diabetes
Disc Salivary Glands
Disc Skin Cancer Diagnosis
Disc Stomach Bloating
Disc Stomach Cramps
Disc Stomach Disorders
Disc Stomach Ulcer
Disc Swollen Pancreas
Disc Testicular Cancer Diagnosis
Disc Thyroid Cancer Diagnosis
Disc Type 1 Diabetes
Disc Type 2 Diabetes
Disc Uterine Cancer Diagnosis
 
Recommended Journals
Disc Endocrinology Journal
Disc Diabetes Journal
Disc Cancer Diagnosis Journal
Disc Pancreas Journal
Disc Gastrointestinal Journal
  View More»
 
Recommended Conferences
Disc Hepatitis Vaccines Summit
Sep 26-28, 2016, Valencia, Spain
Disc 3rd Hepatitis and Liver Diseases Summit
Oct 17-19, 2016, Dubai, UAE
View More»
 
Article Tools
Disc Export citation
Disc Share/Blog this article
 
Article usage
  Total views: 3738
  [From(publication date):
October-2012 - May 29, 2016]
  Breakdown by view type
  HTML page views : 8
  PDF downloads :3730
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

 
OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
 
 
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
 
 

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsinc.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsinc.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsinc.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsinc.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsinc.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsinc.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsinc.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsinc.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsinc.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsinc.com

1-702-714-7001Extn: 9039

Materials Science Journals

Rachle Green

materialsci@omicsinc.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsinc.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsinc.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsinc.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsinc.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsinc.com

1-702-714-7001 Extn: 9042

 
© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version